Presentations 2016
European Public Health Association Conference (EUPHA, Vienna 12 November 2016)

A people-centred health systems approach to hepatitis C elimination in Europe presented by Jeff Lazarus. PRESENTATION. Abstract

AASLD The Liver Meeting, Boston 11-15 November 2016
 

Poster Presentation:
Uptake of HCV treatment in HIV/HCV coinfected patients across Europe in the era of direct-acting antivirals, Presented by Lars Peters. POSTER

HIV Drug Therapy Glasgow 2016, 23-26 October 2016

Oral Presentations:

Initiation of ART early in HIV infection: START to Finish, presented by Jens Lundgren on Monday 24 October 09.30-09:50

Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe, presented by Kamilla Laut. PRESENTATION WEBCAST


Context matters – one stop medical care from Eastern Europe to downtown London, presented by Jeff V Lazarus. ABSTRACT

Differences in virological and immunological risk factors for non-Hodgkin lymphoma (NHL) and Hodgkin (HL): The D:A:D study
Presented by Leah Shepherd on behalf of the DAD Study group on Tuesday 25 October 14.45-15.00 in the co-infections and malignancies-session.PRESENTATION

Thistle Poster Presentations:
The extent of B-cell activation and dysfunction preceding lymphoma development, presented by Alvaro Borges on behalf of Leah Shepherd. Poster no P189 POSTER

Aging and the evolution of comorbidities among HIV patients in the EuroSIDA cohort, presented by Sara Lopes. poster no P154. POSTER


Poster presentations:
Ways in which Legal and Regulatory Barriers Hinder the HIV Care Continuum and 90/90/90 Targets across Europe, presented by Lisa Power on behalf of OptTEST. POSTER

Integrated HIV, Hepatitis B and Hepatitis C testing during the 2015 European Testing Week, presented by Ida Sperle poster no P324. POSTER

Differences in virological and immunological risk factors for non-Hodgkin lymphoma (NHL) and Hodgkin (HL): The D:A:D study
Presented by Leah Shepherd on behalf of the DAD Study group on Tuesday 25 October 14.45-15.00 in the co-infections and malignancies-session. POSTER

Persistent disparities in meeting WHO/UNAIDS targets for ART coverage and ART-induced HIV RNA suppression across Europe,
presented by Kamilla Laut. POSTER

21st International AIDS Conference, Durban 18-22 July 2016

Oral Presentation:
Association between sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy: the PARTNER study presented by Alison Rodger, University College London, United Kingdom . PRESENTATION

Poster Presentations:
Opportunistic diseases among HIV+ people with CD4 counts > 500/mm3: a EuroSIDA study, presented by Alvaro Borges for EuroSIDA in EuroCoord. POSTER

Deferred antiretroviral therapy is associated with lower eGFR in HIV-positive individuals with high CD4 counts. presented by Amanda Mocroft on behalf of the INSIGHT study group. POSTER

TB 2016 Conference, Durban 16-17 July 2016

Poster Presentations:
Management of TB/HIV co-infected patients including MDR-TB in Eastern Europe: Results from the TB:HIV study,
presented by Anne Marie Werlinrud Efsen on behalf of the TB:HIV study group in EuroCoordP37, Abstract 221. POSTER 

Outcomes of efavirenz- and non-efavirenz containing ART in HIV-positive patients co-infected with tuberculosis in Eastern Europe, Western Europe and Latin America, presented by Brenda Crabtree-Ramírez on behalf of the TB:HIV study group in EuroCoord. POSTER

16th International Conference for integrated Care Model Barcelona, Spain 23-25 May 2016

Oral Presentation:
People-centred health services at HIV clinics across Europe: findings from the EuroSIDA clinic survey,
presented by JV Lazarus, K Safreed-Harmon. PRESENTATION 

Conference on Retroviruses and Oppertunistic Infections (CROI) February 2016

 

Oral Presentations:
Antiretrovirals, fractures and osteonecrosis in a large European HIV cohort, presented by Alvaro Borges on behalf of EuroSIDA in EuroCoord. O-4/46. PRESENTATION WEBCAST

Immediate ART Initiation Reduces Risk of Infection-Related Cancer in HIV Infection, presented by Alvaro Borges on behalf of the INSIGHT START study group. O14/160. PRESENTATION VIDEO

Body Composition Changes on Darunavir/Ritonavir (DVR/r) + either Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) as First-Line Antiretroviral Therapy, presented by Jose I. Bernardino for the NEAT 001/ANSR 143 Study Group. O-4/45. PRESENTATION WEBCAST

Poster presentations/ Themed Discussion:
Differences in Predictors for Ischaemic and Haemorrhagic Strokes in HIV+ Individuals, presented by Camilla Ingrid Hatleberg on behalf of the D:A:D study. THEMED DISCUSSION / POSTER
Webcast of Themed Discussion: presentation and discussion

Nature of Immunosuppression and Risk of Chronic Kidney Disease in HIV-positive Persons, presented by Lene Ryom on behalf of the D:A;D study POSTER

Abacavir (ABC) use and risk of recurrent myocardial infarction (MI), presented by Caroline Sabin on behalf of the D:A:D Study. POSTER

Influence of Transmitted Drug Resistance on CD4 Decline among ART Naïve HIV Patientspresented by Anna Schultze on behalf of EuroSIDA in EuroCoord, the EU-Resist collaborating network and the ViroLAB collaboration. P-L1/486. POSTER

Risk factors for Hodgkin (HL) and non-Hodgkin lymphoma (NHL) in Europe, presented by Leah Shepherd on behalf of EuroSIDA in EuroCoord. P-03/630. POSTER